- Home
- Products
- Clinical Trials
- About QI
- Mission Statement
- News
- Publications
- Contact QI
- Resources
- Locating Clinical Trials
- National Cancer Institute
- University of South Alabama
- NCBI
- National Alliance of Breast Cancer
- National Breast Cancer Organization
- National Breast Cancer Coalition
- Young Survival Coalition
- The Mayo Clinic
- Cancer Center of John Hopkins
- Sloan Kettering Cancer Center
- Harvard Cancer Center
 |
|
Charles (Chuck) Broes, Chief Executive Officer; Chairman of the Board |
Mr. Broes is a business and healthcare visionary whose career spans over 45 years in domestic and foreign markets. He has served in various executive roles including COB, CEO, COO, and CIO. He began his unique career with Health Industries (Jack LaLanne European Health Spas) from its founding to becoming a national chain of over one hundred locations, going public and the ultimate sale to a Fortune 500 company. This positioned Mr. Broes to serve in key leadership roles within the healthcare and pharmaceutical industry working with regulatory issues involving the FDA, ISO and CE marking and EDI. Wellmark Corporation, for example, was a pioneer company in healthcare clearinghouse services and ANSI X12 standards, which became a subsidiary of Primark Corporation, a NYSE Company.
Mr. Broes later founded EliteCorp International, Inc. and served as its CEO. In that capacity his experiences have included facilitating public companies, acquisitions, mergers, strategic alliances, IPOs and turnarounds. Associated projects have ranged from concept to development and production, including the integration national data communication networks, facilities management, and healthcare system technologies.
Mr. Broes has served as a member of the Ethics Committee of the Moffitt Cancer Center in Tampa, Florida for fifteen years. In 2008 Mr. Broes turned his full attention to Quantum Immunologics, Inc. (QI) which he helped found and serves as its CEO. QI is a pharmaceutical company now in research, development and implementation of new patented immunotherapy protocols for the treatment of cancer. Clinical trials are currently under way and new patents have been filed providing the company with a pipeline for ongoing improvements in cancer treatment.